Soriacare (IS-217) / Issar - LARVOL DELTA

Strong electric field enhancement near an amorphous silicon metasurface with non-vertical symmetry. (PubMed, Nanoscale Horiz) - "This unique mode is formed by partially breaking the BIC generated from the first excited collective magnetic dipole (MD) resonance in a sub-diffraction periodic system, which exhibits a low group velocity of 16 731 m s-1, while its quality factor (Q factor) is 217. We calculate that the near electric field enhancement reached 808 times at an incident angle θ of 9°22'. Our findings provide unique opportunities for realizing strong-enhanced nonlinear effects in metasurfaces."

Journal

TinyML-Based Lightweight AI Healthcare Mobile Chatbot Deployment. (PubMed, J Multidiscip Healthc) - "The accuracy of the TinyML model is 95.3% and the on-device processing time is 217 ms...Each patient was assigned a unique ID, and their data were securely stored for further consultation and diagnosis via hospital management. This research demonstrates faster patient data recording and increased security compared to existing AI-based healthcare solutions, as all processes occur within the local host."

Journal

Managing relapsed refractory lymphoma with palliative oral chemotherapy: A multicentre retrospective study. (PubMed, EJHaem) - "PEP-C (prednisolone, etoposide, procarbazine and cyclophosphamide) is an orally administered daily chemotherapy regimen used with palliative intent in relapsed refractory lymphoma...The median overall survival of patients with chemosensitive lymphoma treated with PEP-C is 217 days. Within the limitations of a retrospective cohort, we find that PEP-C is well tolerated: the most common toxicity leading to discontinuation is marrow suppression. We suggest that PEP-C should be considered for patients with relapsed refractory lymphoma in two settings: first, where there is no licensed alternative; and second, where the licensed alternative is an intravenous drug and the patient would prefer to choose an oral chemotherapy option."

Journal • Retrospective data • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Oncology